Atrial Flutter Management

Introduction to Atrial Flutter

Atrial flutter represents a macro-reentrant atrial tachycardia that can cause significant symptoms, increase stroke risk, and contribute to heart failure and mortality, according to the American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines 1, 2

The American College of Cardiology recommends catheter ablation as the most appropriate next step in management for patients with recurrent atrial flutter, with a Class I recommendation (highest level) 1, 2
Catheter ablation offers superior long-term maintenance of sinus rhythm compared to pharmacological therapy, with a success rate of over 90% for cavotricuspid isthmus (CTI)-dependent flutter 2
Catheter ablation prevents potential development of tachycardia-mediated cardiomyopathy, a significant benefit for patients with recurrent atrial flutter 2
For non-CTI-dependent (atypical) flutter, catheter ablation is still recommended (Class I) after failure of at least one antiarrhythmic drug, according to the American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines 1, 2

The American College of Cardiology recommends pharmacological therapy with a Class IIa recommendation for maintaining sinus rhythm, but it is associated with significant toxicities and reserved for when other treatments are contraindicated or ineffective 1, 2
Pharmacological therapy has high recurrence rates without addressing the underlying substrate, making it less effective for ongoing management of recurrent atrial flutter 1

The American College of Cardiology recommends ongoing management with antithrombotic therapy in patients with atrial flutter to align with recommendations for atrial fibrillation (Class I), which should be continued even after successful ablation if risk factors for stroke are present 1, 2